Peroxitech Therapeutics operates as a biopharmaceutical company.
Peroxitech Therapeutics operates as a biopharmaceutical company developing PIP-2 to reverse acute lung injury (ALI) by targeting the cytokine storm cascade process.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 13, 2022 | Series A | $25M | 1 | Xontogeny | — | Detail |
May 12, 2021 | Seed | — | 1 | Xontogeny | — | Detail |